全文获取类型
收费全文 | 79137篇 |
免费 | 4296篇 |
国内免费 | 281篇 |
专业分类
耳鼻咽喉 | 1050篇 |
儿科学 | 2167篇 |
妇产科学 | 1859篇 |
基础医学 | 10424篇 |
口腔科学 | 2193篇 |
临床医学 | 6388篇 |
内科学 | 19046篇 |
皮肤病学 | 1595篇 |
神经病学 | 6930篇 |
特种医学 | 2750篇 |
外国民族医学 | 6篇 |
外科学 | 9778篇 |
综合类 | 482篇 |
一般理论 | 26篇 |
预防医学 | 7809篇 |
眼科学 | 1149篇 |
药学 | 5454篇 |
中国医学 | 207篇 |
肿瘤学 | 4401篇 |
出版年
2023年 | 492篇 |
2022年 | 945篇 |
2021年 | 2036篇 |
2020年 | 1157篇 |
2019年 | 1763篇 |
2018年 | 3715篇 |
2017年 | 2376篇 |
2016年 | 1753篇 |
2015年 | 1743篇 |
2014年 | 2415篇 |
2013年 | 3542篇 |
2012年 | 5000篇 |
2011年 | 5218篇 |
2010年 | 2898篇 |
2009年 | 2512篇 |
2008年 | 4445篇 |
2007年 | 4635篇 |
2006年 | 4266篇 |
2005年 | 4287篇 |
2004年 | 3934篇 |
2003年 | 3768篇 |
2002年 | 3561篇 |
2001年 | 1927篇 |
2000年 | 2126篇 |
1999年 | 1614篇 |
1998年 | 641篇 |
1997年 | 465篇 |
1996年 | 445篇 |
1995年 | 400篇 |
1994年 | 348篇 |
1993年 | 323篇 |
1992年 | 758篇 |
1991年 | 635篇 |
1990年 | 634篇 |
1989年 | 564篇 |
1988年 | 503篇 |
1987年 | 509篇 |
1986年 | 464篇 |
1985年 | 445篇 |
1984年 | 341篇 |
1983年 | 320篇 |
1982年 | 210篇 |
1981年 | 203篇 |
1979年 | 266篇 |
1978年 | 225篇 |
1977年 | 187篇 |
1975年 | 207篇 |
1974年 | 194篇 |
1973年 | 228篇 |
1972年 | 199篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
3.
Marike Gabrielson Mattias Hammarström Magnus Bäcklund Jenny Bergqvist Kristina Lång Ann H Rosendahl Signe Borgquist Roxanna Hellgren Kamila Czene Per Hall 《International journal of cancer. Journal international du cancer》2023,152(11):2362-2372
Tamoxifen prevents recurrence of breast cancer and is suggested for preventive risk-reducing therapy. Tamoxifen reduces mammographic density, a proxy for therapy response, but little is known about its effects in remodelling normal breast tissue. Our study, a substudy within the double-blinded dose-determination trial KARISMA, investigated tamoxifen-specific changes in breast tissue composition and histological markers in healthy women. We included 83 healthy women randomised to 6 months daily intake of 20, 10, 5, 2.5, 1 mg of tamoxifen or placebo. The groups were combined to “no dose” (0-1 mg), “low-dose” (2.5-5 mg) or “high-dose” (10-20 mg) of tamoxifen. Ultrasound-guided biopsies were collected before and after tamoxifen exposure. In each biopsy, epithelial, stromal and adipose tissues was quantified, and expression of epithelial and stromal Ki67, oestrogen receptor (ER) and progesterone receptor (PR) analysed. Mammographic density using STRATUS was measured at baseline and end-of-tamoxifen-exposure. We found that different doses of tamoxifen reduced mammographic density and glandular-epithelial area in premenopausal women and associated with reduced epithelium and increased adipose tissue. High-dose tamoxifen also decreased epithelial ER and PR expressions in premenopausal women. Premenopausal women with the greatest reduction in proliferation also had the greatest epithelial reduction. In postmenopausal women, high-dose tamoxifen decreased the epithelial area with no measurable density decrease. Tamoxifen at both low and high doses influences breast tissue composition and expression of histological markers in the normal breast. Our findings connect epithelial proliferation with tissue remodelling in premenopausal women and provide novel insights to understanding biological mechanisms of primary prevention with tamoxifen. 相似文献
4.
5.
6.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
7.
Annals of Nuclear Medicine - The Response Evaluation Criteria In Solid Tumors (RECIST) is the most used radiological method for evaluating response after peptide receptor radionuclide therapy... 相似文献
8.
9.
Francisca Morgado Mariana Batista Ana Moreno Inês Coutinho 《Pediatric dermatology》2021,38(1):191-193
We present a 6‐year‐old girl with skin hyperpigmentation, leukoplakia, and onychodystrophy, the classic mucocutaneous triad usually associated with dyskeratosis congenita. The patient also had premature graying of the hair, bone marrow failure, hepatitis, exudative retinopathy, osteopenia with multiple long bone fractures, and intracranial calcifications and brain cysts. Coats plus syndrome is a rare disease with a clinical and genetic overlap with dyskeratosis congenita. This disease is reviewed, with a focus on the pathogenesis of the genetic anomalies and its background as a telomere biology disorder. 相似文献
10.